Amedeo Smart

Free Medical Literature Service


 

Amedeo

Vaccines

  Free Subscription

Articles published in
Lancet
    September 2022
  1. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.
    >> Share

  2. ZIEGLER T, Moen A, Zhang W, Cox NJ, et al
    Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected.
    Lancet. 2022;400:981-982.
    >> Share

    August 2022
  3. UYEKI TM, Hui DS, Zambon M, Wentworth DE, et al
    Influenza.
    Lancet. 2022;400:693-706.
    >> Share

  4. HILL M, Bandyopadhyay AS, Pollard AJ
    Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use.
    Lancet. 2022 Aug 18. pii: S0140-6736(22)01582.
    >> Share

    July 2022
  5. DURRHEIM DN
    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.
    >> Share

  6. MELLO MM, Opel DJ, Benjamin RM, Callaghan T, et al
    Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)00875.
    >> Share

    June 2022
  7. SACCO C, Del Manso M, Mateo-Urdiales A, Rota MC, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01185.
    >> Share

  8. LADHANI SN
    COVID-19 vaccination for children aged 5-11 years.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01245.
    >> Share

  9. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    >> Share

  10. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    >> Share

  11. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    >> Share

  12. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    >> Share

    May 2022
  13. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    >> Share

  14. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    >> Share

  15. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    >> Share

  16. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    >> Share

  17. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.
    >> Share

    April 2022
  18. ADEPOJU P
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.
    >> Share

  19. NGUYEN-TRAN H, Messacar K
    Preventing enterovirus A71 disease: another promising vaccine for children.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00380.
    >> Share

  20. NGUYEN TT, Chiu CH, Lin CY, Chiu NC, et al
    Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00313.
    >> Share

  21. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.
    >> Share

  22. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.
    >> Share

  23. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    >> Share

  24. WINTER AK, Moss WJ
    Rubella.
    Lancet. 2022;399:1336-1346.
    >> Share

  25. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
    Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Lancet. 2022;399:1313-1321.
    >> Share

  26. BLAKNEY AK, Bekker LG
    DNA vaccines join the fight against COVID-19.
    Lancet. 2022;399:1281-1282.
    >> Share

    March 2022
  27. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
    Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
    Lancet. 2022;399:1225.
    >> Share

  28. NIXON DF, Schwartz RE, Ndhlovu LC
    Booster vaccines for COVID-19 vaccine breakthrough cases?
    Lancet. 2022;399:1224.
    >> Share

  29. BEKKER LG, Garrett N, Goga A, Fairall L, et al
    Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Lancet. 2022;399:1141-1153.
    >> Share

  30. USHER AD
    CEPI launches 100-day vaccine "moonshot".
    Lancet. 2022;399:1107-1108.
    >> Share

  31. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
    Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
    >> Share

  32. MILLS EJ, Reis G
    Evaluating COVID-19 vaccines in the real world.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.
    >> Share

  33. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    >> Share

  34. FALLAH MP, Reinhart E
    Apartheid logic in global health.
    Lancet. 2022;399:902-903.
    >> Share

  35. NUNEZ I
    Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00164.
    >> Share

    February 2022
  36. CHEMAITELLY H, Abu-Raddad LJ
    Waning effectiveness of COVID-19 vaccines.
    Lancet. 2022;399:771-773.
    >> Share


  37. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
    >> Share

  38. BAJAJ SS, Maki L, Stanford FC
    Vaccine apartheid: global cooperation and equity.
    Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.
    >> Share

  39. PIECHOTTA V, Harder T
    Waning of COVID-19 vaccine effectiveness: individual and public health risk.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00282.
    >> Share

  40. FEIKIN DR, Higdon MM, Abu-Raddad LJ, Andrews N, et al
    Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00152.
    >> Share

  41. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    >> Share

  42. MADHI SA, Ihekweazu C, Rees H, Pollard AJ, et al
    Decoupling of omicron variant infections and severe COVID-19.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00109.
    >> Share

  43. EGGER S, Egger G
    The vaccinated propor-tion of people with COVID-19 needs context.
    Lancet. 2022;399:627.
    >> Share

  44. CAPLAN AL
    Stigma, vaccination, and moral accountability.
    Lancet. 2022;399:626-627.
    >> Share

  45. SAMARASEKERA U
    Ayoade Alakija: advancing equity in the COVID-19 response.
    Lancet. 2022;399:511.
    >> Share

  46. BURKI T
    Fresh questions over Gates Foundation governance.
    Lancet. 2022;399:508.
    >> Share

  47. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    >> Share

  48. NORDSTROM P, Ballin M, Nordstrom A
    Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
    Lancet. 2022 Feb 4. pii: S0140-6736(22)00089.
    >> Share

  49. KARAFILLAKIS E, Van Damme P, Hendrickx G, Larson HJ, et al
    COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
    Lancet. 2022 Feb 3. pii: S0140-6736(22)00150.
    >> Share


  50. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    Lancet. 2022 Feb 1. pii: S0140-6736(22)00172.
    >> Share

    January 2022
  51. JAFFE S
    The next steps for US vaccine mandates.
    Lancet. 2022;399:425-426.
    >> Share


  52. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    Lancet. 2022 Jan 27. pii: S0140-6736(22)00101.
    >> Share

  53. HUBSCHEN JM, Gouandjika-Vasilache I, Dina J
    Measles.
    Lancet. 2022 Jan 27. pii: S0140-6736(21)02004.
    >> Share

  54. FENDLER A, Shepherd STC, Au L, Wu M, et al
    Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
    Lancet. 2022 Jan 25. pii: S0140-6736(22)00147.
    >> Share

  55. LANE R
    Jamal Rifi: family doctor building bridges in the community.
    Lancet. 2022;399:353.
    >> Share

  56. COSTA CLEMENS SA, Weckx L, Clemens R, Almeida Mendes AV, et al
    Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00094.
    >> Share

  57. BRAVO L, Smolenov I, Han HH, Li P, et al
    Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00055.
    >> Share

  58. VESIKARI T
    Trimeric S protein COVID-19 vaccine needs to find its place.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00096.
    >> Share

  59. CARR EJ, Wu M, Harvey R, Billany RE, et al
    Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00104.
    >> Share

  60. WU M, Wall EC, Carr EJ, Harvey R, et al
    Three-dose vaccination elicits neutralising antibodies against omicron.
    Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.
    >> Share

  61. KUHLMANN C, Mayer CK, Claassen M, Maponga T, et al
    Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00090.
    >> Share

    December 2021
  62. KING J, Ferraz OLM, Jones A
    Mandatory COVID-19 vaccination and human rights.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02873.
    >> Share

  63. HALPERIN SA, Ye L, MacKinnon-Cameron D, Smith B, et al
    Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02753.
    >> Share

  64. KENNEDY RB
    Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02834.
    >> Share

  65. LEUNG K, Wu JT
    Managing waning vaccine protection against SARS-CoV-2 variants.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02841.
    >> Share

  66. KATIKIREDDI SV, Cerqueira-Silva T, Vasileiou E, Robertson C, et al
    Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02754.
    >> Share

  67. PEELING RW, Heymann DL, Teo YY, Garcia PJ, et al
    Diagnostics for COVID-19: moving from pandemic response to control.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02346.
    >> Share

  68. MCINTYRE PB, Aggarwal R, Jani I, Jawad J, et al
    COVID-19 vaccine strategies must focus on severe disease and global equity.
    Lancet. 2021 Dec 16. pii: S0140-6736(21)02835.
    >> Share

  69. STUART ASV, Shaw RH, Liu X, Greenland M, et al
    Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02718.
    >> Share

  70. RICHARDSON CD
    Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02757.
    >> Share

  71. KARIM SSA, Karim QA
    Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02758.
    >> Share

  72. MENDELSON M, Venter F, Moshabela M, Gray G, et al
    The political theatre of the UK's travel ban on South Africa.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02752.
    >> Share

  73. MUNRO APS, Janani L, Cornelius V, Aley PK, et al
    Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Lancet. 2021 Dec 2. pii: S0140-6736(21)02717.
    >> Share

    November 2021
  74. JAFFE S
    Legal challenges threaten Biden's COVID-19 vaccine rule.
    Lancet. 2021;398:1863-1864.
    >> Share

  75. BURKI T
    mRNA discoveries earn the 2021 Prince Mahidol Award.
    Lancet. 2021;398:1865.
    >> Share

  76. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
    Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
    >> Share

  77. PAVORD S, Scully M, Lester W, Makris M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
    Lancet. 2021;398:1801.
    >> Share

  78. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
    Lancet. 2021;398:1801-1802.
    >> Share

  79. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
    Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
    >> Share

  80. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
    Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
    >> Share

  81. LI JX, Zhu FC
    Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.
    >> Share

  82. ALVES L
    Health experts welcome Brazil COVID-19 inquiry findings.
    Lancet. 2021;398:1674-1675.
    >> Share

  83. USHER AD
    New budget and strategy for ACT-A.
    Lancet. 2021;398:1677.
    >> Share

  84. ZAROCOSTAS J
    WHO's Tedros set to be re-elected unopposed.
    Lancet. 2021;398:1676.
    >> Share

  85. ORTIZ JR, Neuzil KM
    The value of vaccine programme impact monitoring during the COVID-19 pandemic.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.
    >> Share

  86. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    >> Share

  87. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    >> Share

    October 2021
  88. HODGES S, Hornberger J, Kufakurinani U, Rudra S, et al
    When suspicion replaces evidence in public health.
    Lancet. 2021;398:1565-1566.
    >> Share

  89. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    >> Share

  90. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.
    >> Share

  91. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    >> Share

  92. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.
    >> Share

  93. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.
    >> Share

  94. SAMARASEKERA U
    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.
    >> Share

  95. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.
    >> Share

  96. THE LANCET
    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.
    >> Share

  97. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.
    >> Share

  98. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    >> Share

    September 2021
  99. THE LANCET
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.
    >> Share

  100. SHARFSTEIN JM, Callaghan T, Carpiano RM, Sgaier SK, et al
    Uncoupling vaccination from politics: a call to action.
    Lancet. 2021 Sep 16. pii: S0140-6736(21)02099.
    >> Share

  101. KRAUSE PR, Fleming TR, Peto R, Longini IM, et al
    Considerations in boosting COVID-19 vaccine immune responses.
    Lancet. 2021 Sep 14. pii: S0140-6736(21)02046.
    >> Share

  102. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    >> Share

  103. BOSELEY S
    The race to make a COVID-19 vaccine.
    Lancet. 2021;398:832-833.
    >> Share

  104. JERVING S
    The long road ahead for COVID-19 vaccination in Africa.
    Lancet. 2021;398:827-828.
    >> Share

  105. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    >> Share

  106. ROGAWSKI MCQUADE ET, Breskin A
    Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01817.
    >> Share

  107. KASEJE N, Walcott D
    Global youth advocating for COVID-19 vaccines for all.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01994.
    >> Share

  108. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    >> Share

    August 2021
  109. LANGLOIS EV, Dey T, Shah MG
    More than honour, humanitarian health-care workers need life-saving protection.
    Lancet. 2021;398:729-730.
    >> Share

  110. USHER AD
    Health leaders criticise limited ACT-A review.
    Lancet. 2021;398:650-651.
    >> Share

  111. BEHRENS GM, Cossmann A, Stankov MV, Nehlmeier I, et al
    SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.
    Lancet. 2021 Aug 17. pii: S0140-6736(21)01891.
    >> Share

  112. DANIELS JP
    Haiti's health woes intensify.
    Lancet. 2021;398:567.
    >> Share

  113. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.
    Lancet. 2021;398:577-578.
    >> Share

  114. CARR EJ, Wu M, Harvey R, Wall EC, et al
    Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
    Lancet. 2021 Aug 12. pii: S0140-6736(21)01854.
    >> Share

  115. LLOYD-SHERLOCK P, Lasco G, McKee M, Perianayagam A, et al
    Does vaccine ageism amount to gerontocide?
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01689.
    >> Share

  116. KALAFAT E, Magee LA, von Dadelszen P, O'Brien P, et al
    SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity.
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01756.
    >> Share

  117. CRUMP JA, Oo WT
    Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01340.
    >> Share

  118. QADRI F, Khanam F, Liu X, Theiss-Nyland K, et al
    Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01124.
    >> Share

  119. PRIESEMANN V, Balling R, Bauer S, Beutels P, et al
    Towards a European strategy to address the COVID-19 pandemic.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01808.
    >> Share

  120. LEE EJ, Lee AI
    Cerebral venous sinus thrombosis after vaccination: the UK experience.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01788.
    >> Share

  121. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    >> Share

  122. LIU X, Shaw RH, Stuart ASV, Greenland M, et al
    Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01694.
    >> Share

  123. BELDA-INIESTA C
    Optimising SARS-CoV-2 vaccination schedules.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01729.
    >> Share

    July 2021
  124. SHROTRI M, Navaratnam AMD, Nguyen V, Byrne T, et al
    Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
    Lancet. 2021;398:385-387.
    >> Share

  125. KAMPMANN B, Okomo U
    COVID-19 vaccines for children in LMICs: another equity issue.
    Lancet. 2021 Jul 30. pii: S0140-6736(21)01748.
    >> Share

  126. MAKONI M
    Social unrest disrupts South African health care.
    Lancet. 2021;398:287.
    >> Share

  127. REDJOUL R, Le Bouter A, Beckerich F, Fourati S, et al
    Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
    Lancet. 2021;398:298-299.
    >> Share

  128. THE LANCET
    COVID-19 in Africa: a lesson in solidarity.
    Lancet. 2021;398:185.
    >> Share

  129. DANOVARO-HOLLIDAY MC, Kretsinger K, Gacic-Dobo M
    Measuring and ensuring routine childhood vaccination coverage.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01228.
    >> Share

  130. CAUCHEMEZ S, Bosetti P, Kiem CT, Mouro V, et al
    Education and mental health: good reasons to vaccinate children.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01453.
    >> Share

  131. CAUSEY K, Fullman N, Sorensen RJD, Galles NC, et al
    Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01337.
    >> Share


  132. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00984.
    >> Share

  133. THE LANCET
    COVID-19 in Latin America-emergency and opportunity.
    Lancet. 2021;398:93.
    >> Share

  134. TANRIOVER MD, Doganay HL, Akova M, Guner HR, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Lancet. 2021 Jul 8. pii: S0140-6736(21)01429.
    >> Share

  135. GURDASANI D, Drury J, Greenhalgh T, Griffin S, et al
    Mass infection is not an option: we must do more to protect our young.
    Lancet. 2021 Jul 7. pii: S0140-6736(21)01589.
    >> Share

  136. KICKBUSCH I, Leung GM, Shattock RJ
    Learning from crisis: building resilient systems to combat future pandemics.
    Lancet. 2021;398:e2-e6.
    >> Share

    June 2021
  137. WALL EC, Wu M, Harvey R, Kelly G, et al
    AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
    Lancet. 2021 Jun 28. pii: S0140-6736(21)01462.
    >> Share

  138. DANIELS JP
    Colombians protest over inequities and health care.
    Lancet. 2021;397:2454.
    >> Share

  139. SMITH MJ
    What constitutes success in the roll-out of COVID-19 vaccines?
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01244.
    >> Share

  140. DUARTE-SALLES T, Prieto-Alhambra D
    Heterologous vaccine regimens against COVID-19.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01442.
    >> Share

  141. BOROBIA AM, Carcas AJ, Perez-Olmeda M, Castano L, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01420.
    >> Share

  142. THE LANCET
    Protecting refugees during the COVID-19 pandemic.
    Lancet. 2021;397:2309.
    >> Share

  143. USHER AD
    A beautiful idea: how COVAX has fallen short.
    Lancet. 2021;397:2322-2325.
    >> Share

  144. ABECASSIS A
    Five priorities for universal COVID-19 vaccination.
    Lancet. 2021 Jun 17. pii: S0140-6736(21)01371.
    >> Share

  145. SHEIKH A, McMenamin J, Taylor B, Robertson C, et al
    SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
    Lancet. 2021 Jun 14. pii: S0140-6736(21)01358.
    >> Share

  146. GAYTHORPE KAM, Toor J, Echeverria-Londono S, Li X, et al
    Vaccines can save children with non-preventable diseases - Authors' reply.
    Lancet. 2021;397:2251.
    >> Share

  147. SAHA S, Saha SK
    Vaccines can save children with non-preventable diseases.
    Lancet. 2021;397:2250.
    >> Share

  148. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply.
    Lancet. 2021;397:2249-2250.
    >> Share

  149. ROBERTSON JFR, Sewell HF
    COVID-19 vaccine efficacy data: solid enough to delay second dose?
    Lancet. 2021;397:2248-2249.
    >> Share

  150. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.
    Lancet. 2021;397:2248.
    >> Share

  151. MCQUADE ETR, Platts-Mills JA
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
    Lancet. 2021;397:2247-2248.
    >> Share

  152. NASSER A, Zakham F
    A strategy for SARS-CoV-2 vaccination in Yemen.
    Lancet. 2021;397:2247.
    >> Share

  153. GUETL K, Gary T, Raggam RB, Schmid J, et al
    SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.
    Lancet. 2021 Jun 11. pii: S0140-6736(21)01238.
    >> Share

  154. BOLLYKY TJ, Murray CJL, Reiner RC Jr
    Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.
    Lancet. 2021 Jun 8. pii: S0140-6736(21)01323.
    >> Share

  155. KUMAR A, Bernasconi V, Manak M, de Almeida Aranha AP, et al
    The CEPI centralised laboratory network: supporting COVID-19 vaccine development.
    Lancet. 2021;397:2148-2149.
    >> Share

  156. USHER AD
    ACT Accelerator strains donors' aid budgets.
    Lancet. 2021;397:2137.
    >> Share

  157. WALL EC, Wu M, Harvey R, Kelly G, et al
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01290.
    >> Share

  158. NNAJI CA, Ndwandwe D, Lesosky M, Mahomed H, et al
    Tackling missed opportunities for vaccination in a new era of immunisation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01226.
    >> Share

  159. KOSAKA M, Hashimoto T, Ozaki A, Tanimoto T, et al
    Delayed COVID-19 vaccine roll-out in Japan.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01220.
    >> Share

  160. FORMAN R, Jit M, Mossialos E
    Divergent vaccination policies could fuel mistrust and hesitancy.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)01106.
    >> Share

    May 2021
  161. MAKONI M
    Africa's need for more COVID-19 clinical trials.
    Lancet. 2021;397:2037.
    >> Share

  162. JAWAD NK, Taweeleh LA, Elharake JA, Khamis N, et al
    Refugee access to COVID-19 vaccines in Lebanon.
    Lancet. 2021;397:1884.
    >> Share

  163. ZAROCOSTAS J
    What next for a COVID-19 intellectual property waiver?
    Lancet. 2021;397:1871-1872.
    >> Share

  164. LOYO ESL, Gonzalez MJ, Esparza J
    Venezuela is collapsing without COVID-19 vaccines.
    Lancet. 2021;397:1806.
    >> Share

  165. WATSON SI
    Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?
    Lancet. 2021;397:1804-1805.
    >> Share

  166. TORRES I, Lopez-Cevallos D, Artaza O, Profeta B, et al
    Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments.
    Lancet. 2021;397:1804.
    >> Share

  167. HOUSTON AR, Murthy S
    Canada is no global health leader on COVID-19 vaccine equity.
    Lancet. 2021;397:1803.
    >> Share

  168. HOLT E
    Serbia begins paying citizens to receive a COVID-19 vaccine.
    Lancet. 2021;397:1793.
    >> Share

  169. GENC K
    COVID-19 in Turkey: a nation on edge.
    Lancet. 2021;397:1794-1796.
    >> Share

  170. JHA P, Jamison DT, Watkins DA, Bell J, et al
    A global compact to counter vaccine nationalism.
    Lancet. 2021 May 14. pii: S0140-6736(21)01105.
    >> Share

  171. KUPPALLI K, Gala P, Cherabuddi K, Kalantri SP, et al
    India's COVID-19 crisis: a call for international action.
    Lancet. 2021 May 14. pii: S0140-6736(21)01121.
    >> Share

  172. SHAW RH, Stuart A, Greenland M, Liu X, et al
    Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Lancet. 2021 May 12. pii: S0140-6736(21)01115.
    >> Share

  173. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV
    Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.
    Lancet. 2021 May 12. pii: S0140-6736(21)00894.
    >> Share

  174. SAXENA SG, Godfrey T
    Catalysing needed change for health systems in the USA.
    Lancet. 2021;397:1705-1706.
    >> Share

  175. REINHART E, Dawes D, Maybank A
    Structural medicine: towards an economy of care.
    Lancet. 2021;397:1691-1693.
    >> Share

  176. MOORTHY V, Binka F
    R21/Matrix-M: a second malaria vaccine?
    Lancet. 2021 May 5. pii: S0140-6736(21)01065.
    >> Share

  177. DATOO MS, Natama MH, Some A, Traore O, et al
    Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Lancet. 2021 May 5. pii: S0140-6736(21)00943.
    >> Share

  178. HAAS EJ, Angulo FJ, McLaughlin JM, Anis E, et al
    Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Lancet. 2021 May 5. pii: S0140-6736(21)00947.
    >> Share

  179. LESHEM E, Wilder-Smith A
    COVID-19 vaccine impact in Israel and a way out of the pandemic.
    Lancet. 2021 May 5. pii: S0140-6736(21)01018.
    >> Share

  180. BHUYAN A
    Experts criticise India's complacency over COVID-19.
    Lancet. 2021;397:1611-1612.
    >> Share

    April 2021
  181. BURKI T
    Statelessness in the COVID-19 pandemic.
    Lancet. 2021;397:1529-1530.
    >> Share

  182. THE LANCET
    2021: the beginning of a new era of immunisations?
    Lancet. 2021;397:1519.
    >> Share

  183. HALL VJ, Foulkes S, Saei A, Andrews N, et al
    COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00790.
    >> Share

  184. LESHEM E, Lopman BA
    Population immunity and vaccine protection against infection.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00870.
    >> Share

  185. DEAN N
    Hospital admissions due to COVID-19 in Scotland after one dose of vaccine.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00765.
    >> Share

  186. VASILEIOU E, Simpson CR, Shi T, Kerr S, et al
    Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00677.
    >> Share

  187. KHAN MS, Ali SAM, Adelaine A, Karan A, et al
    Rethinking vaccine hesitancy among minority groups.
    Lancet. 2021 Apr 21. pii: S0140-6736(21)00938.
    >> Share

  188. ALVES L
    Brazilian ICUs short of drugs and beds amid COVID-19 surge.
    Lancet. 2021;397:1431-1432.
    >> Share

  189. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    >> Share

  190. MUSTER V, Gary T, Raggam RB, WOlfler A, et al
    Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00871.
    >> Share

  191. MFINANGA SG, Mnyambwa NP, Minja DT, Ntinginya NE, et al
    Tanzania's position on the COVID-19 pandemic.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00678.
    >> Share

  192. CAPUA I, Giaquinto C
    The unsung virtue of thermostability.
    Lancet. 2021;397:1346.
    >> Share

  193. ALI SN, Hanif W, Patel K, Khunti K, et al
    Ramadan and COVID-19 vaccine hesitancy-a call for action.
    Lancet. 2021 Apr 7. pii: S0140-6736(21)00779.
    >> Share

  194. D'SOUZA RS, Wolfe I
    COVID-19 vaccines in high-risk ethnic groups.
    Lancet. 2021 Apr 1. pii: S0140-6736(21)00624.
    >> Share

    March 2021
  195. EMARY KRW, Golubchik T, Aley PK, Ariani CV, et al
    Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00628.
    >> Share

  196. OSTERGAARD SD, Schmidt M, Horvath-Puho E, Thomsen RW, et al
    Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00762.
    >> Share

  197. SANDERS RW, de Jong MD
    Pandemic moves and countermoves: vaccines and viral variants.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00730.
    >> Share

  198. MYLAN S, Hardman C
    COVID-19, cults, and the anti-vax movement.
    Lancet. 2021;397:1181.
    >> Share

  199. USHER AD
    Uncertainties over EU COVID-19 vaccine sharing scheme.
    Lancet. 2021;397:1171.
    >> Share

  200. KLUGE H, McKee M
    COVID-19 vaccines for the European region: an unprecedented challenge.
    Lancet. 2021 Mar 25. pii: S0140-6736(21)00709.
    >> Share


  201. Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00708.
    >> Share

  202. CHANDAN JS, Chandan JK
    Considering gender-based violence in vaccine prioritisation strategies.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00532.
    >> Share

  203. KRISTIANSEN PA, Page M, Bernasconi V, Mattiuzzo G, et al
    WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
    Lancet. 2021 Mar 23. pii: S0140-6736(21)00527.
    >> Share

  204. KARIM SSA
    Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00468.
    >> Share

  205. MUNDT AP
    Assessing government responsibility for COVID-19 deaths.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00529.
    >> Share

  206. SAAH AJ, Munoz N
    Control vaccine formulation - Authors' reply.
    Lancet. 2021;397:1062.
    >> Share

  207. DOSHI P, Hong K, Jefferson T, Jones M, et al
    Control vaccine formulation.
    Lancet. 2021;397:1061-1062.
    >> Share

  208. JAFFE S
    Biden's first legislative victory: $1.9 trillion for COVID-19.
    Lancet. 2021;397:1047-1048.
    >> Share

  209. THE LANCET
    Myanmar's democracy and health on life support.
    Lancet. 2021;397:1035.
    >> Share

  210. BOZORGMEHR K, Jahn R, Stuckler D, McKee M, et al
    Free licensing of vaccines to end the COVID-19 crisis.
    Lancet. 2021 Mar 18. pii: S0140-6736(21)00467.
    >> Share

  211. KRIEGER N, Waterman PD, Chen JT, Testa C, et al
    Missing again: US racial and ethnic data for COVID-19 vaccination.
    Lancet. 2021 Mar 17. pii: S0140-6736(21)00465.
    >> Share

  212. HOLT E
    Countries split from EU on COVID-19 vaccines.
    Lancet. 2021;397:958.
    >> Share

  213. THE LANCET
    Access to COVID-19 vaccines: looking beyond COVAX.
    Lancet. 2021;397:941.
    >> Share

  214. DEVI S
    Health in Syria: a decade of conflict.
    Lancet. 2021;397:955-956.
    >> Share

  215. STEINBERG J, Thomas A, Iravani A
    (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
    Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.
    >> Share

  216. SAMARASEKERA U
    Robin Shattock: novel vaccine developer.
    Lancet. 2021;397:870.
    >> Share

  217. HUNG IFN, Poland GA
    Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
    Lancet. 2021;397:854-855.
    >> Share

  218. VIJAYASINGHAM L, Bischof E, Wolfe J
    Sex-disaggregated data in COVID-19 vaccine trials.
    Lancet. 2021 Mar 5. pii: S0140-6736(21)00384.
    >> Share

    February 2021
  219. BATNIJI R
    Historical evidence to inform COVID-19 vaccine mandates.
    Lancet. 2021;397:791.
    >> Share

  220. CHAUVIN L
    Peruvian COVID-19 vaccine scandal spreads.
    Lancet. 2021;397:783.
    >> Share

  221. ZAROCOSTAS J
    New WTO leader faces COVID-19 challenges.
    Lancet. 2021;397:782.
    >> Share

  222. ADEPOJU P
    Ebola returns to Guinea and DR Congo.
    Lancet. 2021;397:781.
    >> Share

  223. PRENDECKI M, Clarke C, Brown J, Cox A, et al
    Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00502.
    >> Share

  224. MANISTY C, Otter AD, Treibel TA, McKnight A, et al
    Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00501.
    >> Share


  225. Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Feb 24. pii: S0140-6736(21)00372.
    >> Share

  226. SIVA N
    Severe mental illness: reassessing COVID-19 vaccine priorities.
    Lancet. 2021;397:657.
    >> Share

  227. HYDE R
    von der Leyen admits to COVID-19 vaccine failures.
    Lancet. 2021;397:655-656.
    >> Share

  228. VOYSEY M, Costa Clemens SA, Madhi SA, Weckx LY, et al
    Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00432.
    >> Share

  229. SISA I, Noblecilla E, Orozco F
    Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00357.
    >> Share

  230. ROBERTSON JFR, Sewell HF, Stewart M
    Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00455.
    >> Share

  231. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
    Lancet. 2021 Feb 18. pii: S0140-6736(21)00448.
    >> Share

  232. SKEGG D, Gluckman P, Boulton G, Hackmann H, et al
    Future scenarios for the COVID-19 pandemic.
    Lancet. 2021 Feb 16. pii: S0140-6736(21)00424.
    >> Share

  233. MAKONI M
    Tanzania refuses COVID-19 vaccines.
    Lancet. 2021;397:566.
    >> Share

  234. THE LANCET
    Improving prisoner health for stronger public health.
    Lancet. 2021;397:555.
    >> Share

  235. WOUTERS OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, et al
    Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00306.
    >> Share


  236. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00388.
    >> Share

  237. FONTANET A, Autran B, Lina B, Kieny MP, et al
    SARS-CoV-2 variants and ending the COVID-19 pandemic.
    Lancet. 2021 Feb 11. pii: S0140-6736(21)00370.
    >> Share

  238. MARTIN S, Arawi T
    Ensure Palestinians have access to COVID-19 vaccines.
    Lancet. 2021 Feb 9. pii: S0140-6736(21)00190.
    >> Share

  239. BEHRENS RH, Patel V
    Avoiding shoulder injury from intramuscular vaccines.
    Lancet. 2021;397:471.
    >> Share

  240. WARRELL MJ
    Time to revise the strategy for Gavi funding of rabies vaccine?
    Lancet. 2021;397:471-472.
    >> Share

  241. LANE R
    Tahmeed Ahmed: new leader of icddr,b.
    Lancet. 2021;397:463.
    >> Share

  242. LOIZIDES U, Adisa A, de la Rica Manjavacas AL, Robertson JS, et al
    WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00099.
    >> Share

  243. MEREWOOD A, Bode L, Davanzo R, Perez-Escamilla R, et al
    Breastfeed or be vaccinated-an unreasonable default recommendation.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00197.
    >> Share

  244. CLARFIELD AM, Skorecki K, Manor O, Glick S, et al
    A COVID-19 jab in the right direction.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00310.
    >> Share

  245. JONES I, Roy P
    Sputnik V COVID-19 vaccine candidate appears safe and effective.
    Lancet. 2021 Feb 2. pii: S0140-6736(21)00191.
    >> Share

  246. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, et al
    Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
    Lancet. 2021 Feb 2. pii: S0140-6736(21)00234.
    >> Share

  247. FRIESEN P, Caplan AL, Miller JE
    COVID-19 vaccine research and the trouble with clinical equipoise.
    Lancet. 2021 Feb 1. pii: S0140-6736(21)00198.
    >> Share

    January 2021
  248. LI X, Mukandavire C, Cucunuba ZM, Echeverria Londono S, et al
    Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
    Lancet. 2021;397:398-408.
    >> Share

  249. DANIELS JP
    Health experts slam Bolsonaro's vaccine comments.
    Lancet. 2021;397:361.
    >> Share

  250. COHEN AL, Patel MK, Cherian T
    Vaccines work: a reason for celebration and renewed commitment.
    Lancet. 2021;397:351-353.
    >> Share

  251. THE LANCET
    Health and care workers are owed a better future.
    Lancet. 2021;397:347.
    >> Share

  252. BLAKNEY AK, McKay PF
    Next-generation COVID-19 vaccines: here come the proteins.
    Lancet. 2021 Jan 29. pii: S0140-6736(21)00258.
    >> Share

  253. RICHMOND P, Hatchuel L, Dong M, Ma B, et al
    Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Lancet. 2021 Jan 29. pii: S0140-6736(21)00241.
    >> Share


  254. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
    Lancet. 2021 Jan 28. pii: S0140-6736(21)00242.
    >> Share

  255. WATT G, Giacaman R, Zurayk H, Bjertness E, et al
    COVID-19 vaccines for Palestinians.
    Lancet. 2021 Jan 28. pii: S0140-6736(21)00185.
    >> Share

  256. BARDAJI A, Sevene E, Cutland C, Menendez C, et al
    The need for a global COVID-19 maternal immunisation research plan.
    Lancet. 2021 Jan 25. pii: S0140-6736(21)00146.
    >> Share

  257. BHUYAN A
    India begins COVID-19 vaccination amid trial allegations.
    Lancet. 2021;397:264.
    >> Share

  258. MAKONI M
    South Africa responds to new SARS-CoV-2 variant.
    Lancet. 2021;397:267.
    >> Share

  259. USHER AD
    CEPI criticised for lack of transparency.
    Lancet. 2021;397:265-266.
    >> Share

  260. CAVALERI M, Enzmann H, Straus S, Cooke E, et al
    The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
    Lancet. 2021 Jan 13. pii: S0140-6736(21)00085.
    >> Share

  261. STAPLES JE, Alvarez AR
    Public health role for fractional dosage of yellow fever vaccine.
    Lancet. 2021;397:76-77.
    >> Share

  262. JUAN-GINER A, Kimathi D, Grantz KH, Hamaluba M, et al
    Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Lancet. 2021;397:119-127.
    >> Share

  263. GOSTIN LO, Shalala DE, Hamburg MA, Bloom BR, et al
    A global health action agenda for the Biden administration.
    Lancet. 2021;397:5-8.
    >> Share

    December 2020
  264. HARMAN S, Herten-Crabb A, Morgan R, Smith J, et al
    COVID-19 vaccines and women's security.
    Lancet. 2020 Dec 22. pii: S0140-6736(20)32727.
    >> Share

  265. CLAESON M, Hanson S
    COVID-19 and the Swedish enigma.
    Lancet. 2020 Dec 22. pii: S0140-6736(20)32750.
    >> Share

  266. SIVA N
    Experts call to include prisons in COVID-19 vaccine plans.
    Lancet. 2020;396:1870.
    >> Share

  267. BURGESS RA, Osborne RH, Yongabi KA, Greenhalgh T, et al
    The COVID-19 vaccines rush: participatory community engagement matters more than ever.
    Lancet. 2020 Dec 10. pii: S0140-6736(20)32642.
    >> Share

  268. DE COSTER I, Leroux-Roels I, Bandyopadhyay AS, Gast C, et al
    Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32541.
    >> Share

  269. SAEZ-LLORENS X, Bandyopadhyay AS, Gast C, Leon T, et al
    Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32540.
    >> Share

  270. THOMPSON KM
    Poliovirus vaccine options: another step forward.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
    >> Share

  271. ARYEETEY E, Engebretsen E, Gornitzka A, Maassen P, et al
    A step backwards in the fight against global vaccine inequities.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32596.
    >> Share

  272. KNOLL MD, Wonodi C
    Oxford-AstraZeneca COVID-19 vaccine efficacy.
    Lancet. 2020 Dec 8. pii: S0140-6736(20)32623.
    >> Share

  273. VOYSEY M, Clemens SAC, Madhi SA, Weckx LY, et al
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
    Lancet. 2020 Dec 8. pii: S0140-6736(20)32661.
    >> Share

  274. USHER AD
    South Africa and India push for COVID-19 patents ban.
    Lancet. 2020;396:1790-1791.
    >> Share

  275. THE LANCET
    An African plan to control COVID-19 is urgently needed.
    Lancet. 2020;396:1777.
    >> Share

  276. MULHOLLAND K, Kretsinger K, Wondwossen L, Crowcroft N, et al
    Action needed now to prevent further increases in measles and measles deaths in the coming years.
    Lancet. 2020;396:1782-1784.
    >> Share

    November 2020
  277. THE LANCET
    COVID-19 vaccines: no time for complacency.
    Lancet. 2020;396:1607.
    >> Share

  278. RAMASAMY MN, Minassian AM, Ewer KJ, Flaxman AL, et al
    Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Lancet. 2020 Nov 18. pii: S0140-6736(20)32466.
    >> Share

  279. ANDREW MK, McElhaney JE
    Age and frailty in COVID-19 vaccine development.
    Lancet. 2020 Nov 18. pii: S0140-6736(20)32481.
    >> Share

  280. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
    Lancet. 2020;396:1486-1487.
    >> Share

  281. LODGE A
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lancet. 2020;396:1486.
    >> Share

  282. CHAUHAN A, Agarwal A, Jaiswal N, Singh M, et al
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lancet. 2020;396:1485-1486.
    >> Share

  283. HORTON R
    Offline: Managing the COVID-19 vaccine infodemic.
    Lancet. 2020;396:1474.
    >> Share

  284. SMITH MJ, Ujewe S, Katz R, Upshur REG, et al
    Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.
    Lancet. 2020 Nov 5. pii: S0140-6736(20)32337.
    >> Share

  285. ANDERSON RM, Vegvari C, Truscott J, Collyer BS, et al
    Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
    Lancet. 2020 Nov 4. pii: S0140-6736(20)32318.
    >> Share

    October 2020
  286. HASSAN-SMITH Z, Hanif W, Khunti K
    Who should be prioritised for COVID-19 vaccines?
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32224.
    >> Share

  287. BINGHAM K
    The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world.
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32175.
    >> Share

  288. KRAUSE PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, et al
    Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32259.
    >> Share

  289. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    Use of adenovirus type-5 vectored vaccines: a cautionary tale.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32156.
    >> Share

  290. WARD BJ, Makarkov A, Seguin A, Pillet S, et al
    Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (>/=65 years): two multicentre, randomised phase 3 trials.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32014.
    >> Share

  291. POLAND GA, Ovsyannikova IG, Kennedy RB
    SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32137.
    >> Share

  292. TREGONING JS
    First human efficacy study of a plant-derived influenza vaccine.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32010.
    >> Share

  293. MCMAHON JH, Hoy JF, Kamarulzaman A, Bekker LG, et al
    Leveraging the advances in HIV for COVID-19.
    Lancet. 2020;396:943-944.
    >> Share

    September 2020
  294. LOGUNOV DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV, et al
    Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31970.
    >> Share

  295. PEIRIS M, Leung GM
    What can we expect from first-generation COVID-19 vaccines?
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31976.
    >> Share

  296. BUCCI E, Andreev K, Bjorkman A, Calogero RA, et al
    Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31960.
    >> Share

  297. THE LANCET
    Global collaboration for health: rhetoric versus reality.
    Lancet. 2020;396:735.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016